This website uses cookies to improve performance, functionality and user experience. By agreeing to continue to browse our website, you are providing consent to the use of cookies. Please see our Privacy Policy for details on how we use cookies.
The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting (ASM) 2021 is being held virtually from 23rd June to 25th June 2021.
Recognised as the leading scientific meeting for paediatric oncology in Australia and New Zealand, the ANZCHOG ASM 2021 will bring together paediatric oncologists haematologists, nurses, allied and mental health professionals, research scientists, clinical research professionals, parents and consumers, to discuss the latest developments in research and treatment.
This year’s theme is: “Clinical decision-making in a time of precision, hope and uncertainty.”
This broad theme will encompass the increasingly complex decision-making needed as precision medicine and advanced genomics/epigenomics expands at a breath-taking pace, and our need to be mindful of the hope and uncertainty this creates for families and clinicians. It includes challenging clinical and ethical decision-making related to relapsed disease, difficult-to-treat cancers, and end-of-life care.
The theme embraces the breadth of clinical decision-making across medical, nursing, psychosocial and allied health staff and the contributions families make in shared decision-making processes.
ASM sessions will include precision medicine; survivorship; palliative care; ethics and drug access and cancer treatment in developing countries.
The Annual Scientific Meeting 2021 Virtual registration is now available . Click below for more information.
Exciting opportunities to engage with more colleagues than ever before
Don’t miss any parallel talks or engaging Q&A sessions
1 month access to all program content and materials to review at your leisure
© 2021 ANZCHOG 2021. All Rights Reserved.
Designed and built by MCI Australia
This website uses cookies to improve performance, functionality and user experience. By agreeing to continue to browse our website, you are providing consent to the use of cookies. Please see our Privacy Policy for details on how we use cookies.
Dr. Patrick Brown is Professor of Oncology and Pediatrics and Director of the Pediatric Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine in Baltimore. He is the Vice Chair for relapse and an executive steering committee member of the ALL Committee in the Children’s Oncology Group, and chairs the National Comprehensive Cancer Network’s Clinical Guidelines Panels for adult and pediatric ALL. His research focuses on developing molecularly targeted therapies for high risk childhood leukemias.
A/Prof Maria McCarthy is a Senior Mental Health Clinician in the Children’s Cancer Centre (CCC) at the Royal Children’s Hospital, Melbourne and leads a team of clinicians who provide psychosocial support to children who are being treated for cancer and other haematological conditions, and their families.
As a clinician-scientist, Maria also holds positions as a Senior Research Fellow with the Murdoch Children’s Research Institute and an Honorary Principal Fellow with the University of Melbourne Department of Paediatrics. In these roles Maria oversees clinical trials, and leads both quality of life and intervention research with a specific focus on translating findings into clinical initiatives. This has resulted in a comprehensive suite of clinical programs which aim to optimise psychological, educational and social outcomes for children and their families who are treated for serious illnesses through the CCC.
Lynn Gillam is an experienced clinical ethicist, originally trained in philosophy (MA, Oxon, as a Rhodes Scholar) and bioethics (PhD). Lynn is the Academic Director of the Children’s Bioethics Centre at the Royal Children’s Hospital Melbourne. She is also Professor in Health Ethics at the University of Melbourne, in the Melbourne School of Population and Global Health.
Lynn provides clinical ethics case consultation, policy advice and leads research in paediatric clinical ethics. In 2018, Lynn was awarded the RCH Chairman’s Medal, in recognition of this work.
She also teaches ethics in the MD course, and supervises research students.
Martha Grootenhuis is head of the Psycho-oncology team at the Princess Máxima Center in the Netherlands. As principal investigator she leads a research group focused on psychosocial aspects of cancer treatment of children, and family members. These include consequences such as medical traumatic stress, anxiety and depression, but also quality of life and sleep. Her group focuses on the early recognition and treatment of these problems, using innovatiove web-based applications for monitoring and screening, and for group interventions. Effectiveness research and implementation of interventions are part of the research program. She is professor of Pediatric Psycho-Oncology at Utrecht University. She is founder and chairperson of the Pediatric Psycho-Oncology Committee of the International Society of Pediatric Oncology (SIOP).
Dr. Mabbott received his PhD in developmental psychology at the University of Alberta in 1998 and then completed a post-doctoral fellowship in paediatric neuropsychology at The Hospital for Sick Children (SickKids).
Dr. Mabbott is Head of Neurosciences and Mental Health Program and Senior Scientist within the Research Institute at SickKids and a Professor in the Department of Psychology at the University of Toronto. Situated at the intersection between clinical neuroscience, developmental neuropsychology, and regenerative medicine, Dr. Mabbott’s research program seeks to: (a) understand how perturbed brain development manifests as cognitive impairment in children – particularly in survivors of paediatric brain tumours, and (b) discover how neuroplasticity in the developing brain can be harnessed for neural recovery and cognitive restoration in children with acquired brain injury. His work has been instrumental in documenting the thinking and learning problems children and adolescents treated for brain tumours experience, and the underlying damage to brain structure and function that cause these problems.
He is now conducting exciting new work to find ways to foster brain repair and cognitive recovery following acquired brain injury in children, including harnessing neuroplasticity from physical exercise and employing drugs that stimulate the growth of new brain cells.
Vijay is originally from Northern Alberta and completed his MD (2005) and Child Neurology Residency (2010) at the University of Alberta in Edmonton, Alberta. He then completed a Pediatric Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York, and proceeded to return to Canada where he completed his PhD in Cancer Genomics at the University of Toronto under the supervision of Dr. Michael Taylor.
He is currently a Staff Neuro-Oncologist at the Hospital for Sick Children, Principal Investigator in the Arthur and Sonia Labatt Brain Tumour Research Centre, and an Assistant Professor in the Department of Medical Biophysics at the University of Toronto. His research works have focused on the genomics of medulloblastoma and ependymoma, with a specific interest in recurrent disease. His laboratory is focused on improving classification and identification of novel therapies for recurrent ependymoma and medulloblastoma.
bio